SHARE NOW
CancerVAX has expanded its development pipeline to include a universal CAR-T cell platform that may have the potential to majorly reduce the costs of CAR-T cell therapies by helping the body produce its own CAR-T cells.
Preclinical biotechnology company CancerVAX, which works alongside UCLA, has announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically reduce the cost of CAR-T cell cancer therapies.
Due to cell therapy’s complicated and expensive nature, costs vary greatly, starting from $500,000 per dose. CancerVAX believes it can dramatically cut the costs by a few thousand dollars per dose by helping the body produce its own CAR T-cells.
Ryan Davies, CEO of CancerVAX commented, “CAR-T cell therapy is one of the more promising immunotherapies entering the mainstream of cancer treatment. There are currently six FDA approved CAR-T cell therapies, and they all cost around $500,000 per dose.”
The UCLA research team recently reported a significant process of the project during a meeting with Company executives. Alluded from their recent findings, the adaption to carry genetic instructions to reprogram T-cells into CAR-T cells inside the body (in-vivo) can be achieved by the foundational nanoparticle technology developed for the current Universal Cancer Vaccine project. Depending on the specific genetic instructions provided, the new CAR-T cells will be able to target the different cancers. Positive preliminary lab tests led to the company’s decision to expand its development pipeline to include a ‘Universal Cart-T Platform.’
How are you enjoying this news article? Let us know your thoughts, here >>
CancerVAX’s vision of its CAR-T treatment process is to load the genetic codes of specific proteins on cancer cells onto smart nanoparticles using an innovative high-speed, low-cost manufacturing process. In conventional CAR-T cell therapy, the patient’s T cells are removed from their blood, CAR is inserted into the T cells in the laboratory for gene editing, initiating the expression of T-cell receptors to bind to the cancer cell’s antigens. These CAR-T cells are then grown in the laboratory.
Millions of CancerVAX’s nanoparticles are injected into the patient as a single shot. The nanoparticles attach to the patient’s natural T-cells inside the body, unload the genetic code, and reprogram the T-cells to target specific cancer cells and kill them. Convectional CAR-T cell therapy uses intravenous infusion to deliver lab-grown CAR-T cells to the patient where the CAR proteins on the surface of the CAR-T cells bind to antigens on the cancer cells and kill them.
CancerVAX’s current pipeline with UCLA consists of three projects:
- Children’s Cancer – Immunotherapy treatments for Ewing sarcoma, a children’s bone and tissue cancer with 100% death rate for recurrence.
- Universal Cancer Vaccine Platform – A novel and customizable Universal Cancer Vaccine (UCV), to be delivered as a shot, that can uniquely detect, mark and kill only cancer cells.
- Universal CAR-T Cell Platform – A novel and customizable low-cost treatment, to be delivered as a shot, that can reprogram natural immune T-cells inside the body to seek and destroy targeted cancer cells.
“While no amount of money is too much to save a single human life, we hope to dramatically lower the cost of CAR-T cell therapy by several orders of magnitude and help save many lives. The extreme low cost of the COVID vaccine, which uses similar technology and concepts, leads us to believe that this major cost reduction is possible with our Universal CAR-T Cell platform,” Davies concluded.
Source: CancerVAX Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
